Detalhe da pesquisa
1.
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 403(10423): 249-260, 2024 Jan 20.
Artigo
Inglês
| MEDLINE | ID: mdl-38048786
2.
Imetelstat in intermediate-2 or high-risk myelofibrosis refractory to JAK inhibitor: IMpactMF phase III study design.
Future Oncol
; 18(22): 2393-2402, 2022 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-35510486
3.
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
Am J Hematol
; 95(6): 594-603, 2020 06.
Artigo
Inglês
| MEDLINE | ID: mdl-32129512
4.
Population pharmacokinetics of imetelstat, a first-in-class oligonucleotide telomerase inhibitor.
CPT Pharmacometrics Syst Pharmacol
; 2024 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38771074
5.
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2.
Front Oncol
; 8: 253, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30087850
6.
nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.70+ Study in Elderly Patients With Advanced NSCLC.
Front Oncol
; 8: 262, 2018.
Artigo
Inglês
| MEDLINE | ID: mdl-30087851
7.
'No child need have rickets' revisited.
J Pediatr Endocrinol Metab
; 21(2): 107-8, 2008 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-18422022